Aaron Osborne Net Worth

Aaron Osborne biography

Dr. Aaron Osborne serves as Chief Medical Officer of the Company. Dr. Osborne has served as our chief medical officer since April 2019. Dr. Osborne has over twelve years of experience in the biopharmaceutical industry together with five years of clinical practice in the British National Health Service as an ophthalmologist. Prior to joining Adverum, Dr. Osborne was principal medical director since September 2018, and senior medical director from September 2015 through August 2018, of Ophthalmology Product Development at Genentech Inc., a biotechnology company, where he was responsible for leading clinical development programs for faricimab in wet age-related macular degeneration and diabetic macular edema, and academic collaborations. From August 2013 through May 2015, Dr. Osborne was the pharmaceuticals franchise head, Global Medical Affairs for Alcon Research Ltd., an eye care company, where he was responsible for developing global medical affairs plans for strategic marketed Alcon brands and for medical communications around Alcon retina programs. Prior to Alcon, Dr. Osborne served as global medical affairs head, Ophthalmics, at Novartis Pharma AG from December 2012 to August 2013, and as global brand medical director, Lucentis, at Novartis Pharma AG from December 2010 to August 2013. Dr. Osborne trained in ophthalmology at Queens Medical Center, Nottingham, and earned his Bachelor of Medicine, Bachelor of Surgery (MBBS) degree at University College London.

What is the salary of Aaron Osborne?

As the Chief Medical Officer of Adverum Biotechnologies Inc, the total compensation of Aaron Osborne at Adverum Biotechnologies Inc is 2,382,200$. There are 2 executives at Adverum Biotechnologies Inc getting paid more, with Leone Patterson having the highest compensation of 2,830,320$.

How old is Aaron Osborne?

Aaron Osborne is 46, he's been the Chief Medical Officer of Adverum Biotechnologies Inc since 2019. There are 15 older and 3 younger executives at Adverum Biotechnologies Inc. The oldest executive at Adverum Biotechnologies Inc is Richard Spivey, 69, who is the Independent Director.

What's Aaron Osborne's mailing address?

Aaron's mailing address filed with the SEC is C/O ADVERUM BIOTECHNOLOGIES, INC., 800 SAGINAW DRIVE, REDWOOD CITY, CA, 94063.

Insiders trading at Adverum Biotechnologies Inc

Over the last 9 years, insiders at Adverum Biotechnologies Inc have traded over 1,591,374$ worth of Adverum Biotechnologies Inc stock and bought 912,973 units worth 4,153,055$ . The most active insiders traders include Patrick Machado、Braden Michael Leonard、Thomas Woiwode. On average, Adverum Biotechnologies Inc executives and independent directors trade stock every 40 days with the average trade being worth of 200,186$. The most recent stock trade was executed by Braden Michael Leonard on 30 July 2024, trading 85,800 units of ADVM stock currently worth 613,470$.

What does Adverum Biotechnologies Inc do?

adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.

Adverum Biotechnologies Inc executives and stock owners

Adverum Biotechnologies Inc executives and other stock owners filed with the SEC include:

• Leone Patterson,
  President
• Thomas Leung,
  Chief Financial Officer
• Aaron Osborne,
  Chief Medical Officer
• Dr. Laurent Fischer,
  Pres, CEO, Interim CMO & Director
• Dr. Brigit Riley Ph.D.,
  Chief Scientific Officer
• Rekha Hemrajani,
  Independent Director
• James Scopa,
  Independent Director
• Mark Lupher,
  Independent Director
• Patrick Machado,
  Independent Chairman of the Board
• Richard Spivey,
  Independent Director
• Eric Carter,
  Independent Director
• Thomas Woiwode,
  Independent Director
• Mehdi Gasmi,
  Director
• Myesha Lacy,
  Vice President, Investor Relations and Corporate Communications
• Scott Whitcup,
  Independent Director
• Peter Soparkar,
  Chief legal officer
• Christopher Morrison,
  Vice President - Process Development
• Thomas Kochy,
  Vice President - Commercial and Program Strategy
• Heikki Jouttijarvi,
  Vice President - Manufacturing
• Angela Thedinga,
  Chief Technology Officer
• Laurent Fischer,
  Chief Executive Officer, Director
• Carla Fiankan,
  Sr. VP of Regulatory Affairs
• Nancy E. Pecota,
  Principal Accounting Officer
• John W. Rakow J.D.,
  Sr. VP, Gen. Counsel & Acting CFO
• Anand Reddi,
  VP, Head of Corp. Strategy & External Affairs and Engagement
• Michael Steel,
  Sr. VP of Quality
• Dr. Jim Wang Ph.D.,
  Sr. VP & Head of Regulatory Affairs
• Dena House,
  Sr. VP of HR, Organizational Devel. & Learning
• Kishor Peter Soparkar J.D.,
  Chief Operating Officer
• Dr. Rupert D'Souza M.B.A., Ph.D.,
  Chief Financial Officer
• Steven Daniel Schwartz,
  Director
• Samuel B. Barone,
  SVP, Clinical Development
• Athena Countouriotis,
  SVP, Chief Medical Officer
• Mitchell H. Finer,
  Director
• Carlo Russo,
  EVP and Chief Medical Officer
• Jennifer C. Cheng,
  General Counsel
• Amber Salzman,
  President and CEO
• Paul B Cleveland,
  Chief Executive Officer
• Richard Beckman,
  Chief Medical Officer
• Szilard Kiss,
  
• Soo Hong,
  
• Rabia Gurses Ozden,
  Chief Medical Officer
• Linda M Rubinstein,
  CHIEF FINANCIAL OFFICER
• Dawn Svoronos,
  
• Reed Vaughn Tuckson,
  
• Rupert D'souza,
  Chief Financial Officer
• Julie Clark,
  Chief Medical Officer
• Setareh Seyedkazemi,
  CHIEF DEVELOPMENT OFFICER
• Braden Michael Leonard,
  
• Brigit Riley,
  Chief Scientific Officer
• John Rakow,
  SVP, Genl Counsel, Acting CFO
• C. David Nicholson,,